- Home
- MVST vs AMRN Comparison
MVST vs AMRN Comparison
Compare MVST & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.56
HOLD
Current Price
$14.83
Company Overview
Basic Information| Metric | MVST | AMRN |
|---|---|---|
| Founded | 2006 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 339.8M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | MVST | AMRN |
|---|---|---|
| Price | $1.56 | $14.83 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 4.6M | 78.6K |
| Earning Date | 03-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | $29.85 | N/A |
| Revenue Next Year | $36.59 | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $1.09 | $0.39 |
| 52 Week High | $7.12 | $20.90 |
Technical Indicators
Market Signals| Indicator | MVST | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 33.07 | 44.69 |
| Support Level | $1.51 | $13.63 |
| Resistance Level | $2.49 | $14.55 |
| Average True Range (ATR) | 0.15 | 0.73 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 4.72 | 23.71 |
Price Performance
Historical Comparison MVST
AMRN
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.